These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
441 related articles for article (PubMed ID: 31209714)
1. Detection of Circulating Tumor DNA with a Single-Molecule Sequencing Analysis Validated for Targeted and Immunotherapy Selection. Atkins A; Gupta P; Zhang BM; Tsai WS; Lucas J; Javey M; Vora A; Mei R Mol Diagn Ther; 2019 Aug; 23(4):521-535. PubMed ID: 31209714 [TBL] [Abstract][Full Text] [Related]
2. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. Al Zoughbi W; Fox J; Beg S; Papp E; Hissong E; Ohara K; Keefer L; Sigouros M; Kane T; Bockelman D; Nichol D; Patchell E; Bareja R; Karandikar A; Alnajar H; Cerqueira G; Guthrie VB; Verner E; Manohar J; Greco N; Wilkes D; Tagawa S; Malbari MS; Holcomb K; Eng KW; Shah M; Altorki NK; Sboner A; Nanus D; Faltas B; Sternberg CN; Simmons J; Houvras Y; Molina AM; Angiuoli S; Elemento O; Mosquera JM Oncologist; 2021 Nov; 26(11):e1971-e1981. PubMed ID: 34286887 [TBL] [Abstract][Full Text] [Related]
3. Accuracy and reproducibility of somatic point mutation calling in clinical-type targeted sequencing data. Karimnezhad A; Palidwor GA; Thavorn K; Stewart DJ; Campbell PA; Lo B; Perkins TJ BMC Med Genomics; 2020 Oct; 13(1):156. PubMed ID: 33059707 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors. Froyen G; Geerdens E; Berden S; Cruys B; Maes B Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626061 [TBL] [Abstract][Full Text] [Related]
5. Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors. Akolkar D; Patil D; Srivastava N; Patil R; Datta V; Apurwa S; Yashwante N; Dhasarathan R; Gosavi R; John J; Khan S; Jadhav N; Mene P; Ahire D; Pawar S; Bodke H; Sahoo S; Nile A; Saindane D; Darokar H; Devhare P; Srinivasan A; Datar R PLoS One; 2021; 16(2):e0246048. PubMed ID: 33556149 [TBL] [Abstract][Full Text] [Related]
6. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691 [TBL] [Abstract][Full Text] [Related]
7. Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA. Poh J; Ngeow KC; Pek M; Tan KH; Lim JS; Chen H; Ong CK; Lim JQ; Lim ST; Lim CM; Goh BC; Choudhury Y PLoS One; 2022; 17(4):e0267389. PubMed ID: 35486650 [TBL] [Abstract][Full Text] [Related]
9. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma. Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033 [TBL] [Abstract][Full Text] [Related]
10. Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. Clark TA; Chung JH; Kennedy M; Hughes JD; Chennagiri N; Lieber DS; Fendler B; Young L; Zhao M; Coyne M; Breese V; Young G; Donahue A; Pavlick D; Tsiros A; Brennan T; Zhong S; Mughal T; Bailey M; He J; Roels S; Frampton GM; Spoerke JM; Gendreau S; Lackner M; Schleifman E; Peters E; Ross JS; Ali SM; Miller VA; Gregg JP; Stephens PJ; Welsh A; Otto GA; Lipson D J Mol Diagn; 2018 Sep; 20(5):686-702. PubMed ID: 29936259 [TBL] [Abstract][Full Text] [Related]
11. Machine learning random forest for predicting oncosomatic variant NGS analysis. Pellegrino E; Jacques C; Beaufils N; Nanni I; Carlioz A; Metellus P; Ouafik L Sci Rep; 2021 Nov; 11(1):21820. PubMed ID: 34750410 [TBL] [Abstract][Full Text] [Related]
12. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. Conroy JM; Pabla S; Glenn ST; Seager RJ; Van Roey E; Gao S; Burgher B; Andreas J; Giamo V; Mallon M; Lee YH; DePietro P; Nesline M; Wang Y; Lenzo FL; Klein R; Zhang S PLoS One; 2021; 16(12):e0260089. PubMed ID: 34855780 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081 [TBL] [Abstract][Full Text] [Related]
14. Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing. Fernandez SV; Tan YF; Rao S; Fittipaldi P; Sheriff F; Borghaei H; Dotan E; Winn JS; Edelman MJ; Treat J; Judd J; Alpaugh RK; Wang YL; Yu JQ; Wasik M; Baldwin DA Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958763 [TBL] [Abstract][Full Text] [Related]
15. Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors. Kim M; Lee C; Hong J; Kim J; Jeong JY; Park NJ; Kim JE; Park JY Cancer Res Treat; 2023 Apr; 55(2):429-441. PubMed ID: 36470260 [TBL] [Abstract][Full Text] [Related]
16. Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. Garcia EP; Minkovsky A; Jia Y; Ducar MD; Shivdasani P; Gong X; Ligon AH; Sholl LM; Kuo FC; MacConaill LE; Lindeman NI; Dong F Arch Pathol Lab Med; 2017 Jun; 141(6):751-758. PubMed ID: 28557599 [TBL] [Abstract][Full Text] [Related]
17. Analytical validation and clinical utilization of K-4CARE™: a comprehensive genomic profiling assay with personalized MRD detection. Nguyen Hoang TP; Nguyen TA; Tran NHB; Nguyen Hoang VA; Thi Dao HT; Tran VU; Nguyen YN; Nguyen AT; Nguyen Thi CT; Do Thi TT; Nguyen DS; Nguyen HN; Giang H; Tu LN Front Mol Biosci; 2024; 11():1334808. PubMed ID: 38404964 [No Abstract] [Full Text] [Related]
18. Technical Validation of a Next-Generation Sequencing Assay for Detecting Actionable Mutations in Patients with Gastrointestinal Cancer. Wang SR; Malik S; Tan IB; Chan YS; Hoi Q; Ow JL; He CZ; Ching CE; Poh DYS; Seah HM; Cheung KHT; Perumal D; Devasia AG; Pan L; Ang S; Lee SE; Ten R; Chua C; Tan DSW; Qu JZZ; Bylstra YM; Lim L; Lezhava A; Ng PC; Wong CW; Lim T; Tan P J Mol Diagn; 2016 May; 18(3):416-424. PubMed ID: 26970585 [TBL] [Abstract][Full Text] [Related]
19. SNooPer: a machine learning-based method for somatic variant identification from low-pass next-generation sequencing. Spinella JF; Mehanna P; Vidal R; Saillour V; Cassart P; Richer C; Ouimet M; Healy J; Sinnett D BMC Genomics; 2016 Nov; 17(1):912. PubMed ID: 27842494 [TBL] [Abstract][Full Text] [Related]
20. Evaluating the Calling Performance of a Rare Disease NGS Panel for Single Nucleotide and Copy Number Variants. Cacheiro P; Ordóñez-Ugalde A; Quintáns B; Piñeiro-Hermida S; Amigo J; García-Murias M; Pascual-Pascual SI; Grandas F; Arpa J; Carracedo A; Sobrido MJ Mol Diagn Ther; 2017 Jun; 21(3):303-313. PubMed ID: 28290094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]